Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: Insights from the aspirant trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00077045" target="_blank" >RIV/00216224:14110/14:00077045 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/14:33151449 RIV/00098892:_____/14:#0000781

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2012.105" target="_blank" >http://dx.doi.org/10.5507/bp.2012.105</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2012.105" target="_blank" >10.5507/bp.2012.105</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: Insights from the aspirant trial

Popis výsledku v původním jazyce

Methods. Patients with an office systolic blood pressure (BP) &gt;140 mmHg or diastolic BP &gt;90 mmHg, despite treatment with at least 3 antihypertensive drugs including a diuretic, were randomly assigned to receive spironolactone or a placebo for 8 weeks in a double-blind, placebo-controlled, multicentre trial (ASPIRANT). Background. There are currently limited data on whether the effect of spironolactone in patients with resistant arterial hypertension depends on age and sex. Results. Analyses were done on 55 patients treated with spironolactone and 56 patients treated with placebo. Significant reductions of office systolic BP (-8.9 +/- 6.7 mmHg, P=0.012), 24-h ABPM systolic BP (-7.9 +/- 7.2 mmHg, P=0.032) and ABPM day-time systolic BP (-7.5 +/- 7.1mmHg) after 8 weeks of spironolactone treatment, compared to placebo, were only observed in patients with a median age 62 years, and is effective to a similar extent in men and women.

Název v anglickém jazyce

Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: Insights from the aspirant trial

Popis výsledku anglicky

Methods. Patients with an office systolic blood pressure (BP) &gt;140 mmHg or diastolic BP &gt;90 mmHg, despite treatment with at least 3 antihypertensive drugs including a diuretic, were randomly assigned to receive spironolactone or a placebo for 8 weeks in a double-blind, placebo-controlled, multicentre trial (ASPIRANT). Background. There are currently limited data on whether the effect of spironolactone in patients with resistant arterial hypertension depends on age and sex. Results. Analyses were done on 55 patients treated with spironolactone and 56 patients treated with placebo. Significant reductions of office systolic BP (-8.9 +/- 6.7 mmHg, P=0.012), 24-h ABPM systolic BP (-7.9 +/- 7.2 mmHg, P=0.032) and ABPM day-time systolic BP (-7.5 +/- 7.1mmHg) after 8 weeks of spironolactone treatment, compared to placebo, were only observed in patients with a median age 62 years, and is effective to a similar extent in men and women.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers of the Faculty of Medicine and Dentistry of Palacký University, Olomouc, Czech Republic

ISSN

1213-8118

e-ISSN

—

Svazek periodika

158

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

384-390

Kód UT WoS článku

000345398500009

EID výsledku v databázi Scopus

—